廖中廷 李娟 兰霞

    [摘要] 目的 探讨外周血淋巴细胞/单核细胞比值(LMR)对多发性骨髓瘤(MM)预后判断的应用价值。 方法 系统性回顾100例2013年1月—2019年1月于四川省资阳市人民医院接受新药蛋白酶体抑制剂和/或免疫调节药物治疗的MM患者的总生存期，用受试者工作特性曲线(ROC)等指标评估LMR对预后的影响。 结果 ROC曲线下面积为0.612，对应的最佳诊断阈值为4.0，即LMR≤4.0的MM患者的总生存期短于LMR>4.0的患者。 结论 LMR作为血常规简单的计算结果，是接受新药治疗的MM患者临床预后的一项简单、经济指标。

    [关键词] 淋巴细胞/单核细胞比值;多发性骨髓瘤;受试者工作特性曲线;预后价值

    [中图分类号] R733.3 ? ? ? ? ?[文献标识码] A ? ? ? ? ?[文章编号] 1673-7210(2020)08(b)-0082-04

    [Abstract] Objective To explore the prognostic value of the peripheral blood lymphocyte-to-monocyte ratio (LMR) on multiple myeloma (MM). Methods The overall survival of 100 MM patients who received new proteasome inhibitors and/or immunomodulatory drugs from January 2013 to January 2019 in the People′s Hospital of Ziyang， Sichuan Province was systematically reviewed， and the effect of LMR on prognosis was evaluated by the receiver operating characteristic curve (ROC) and other indicators. Results The area under the ROC curve was 0.612 and the corresponding optimal diagnostic threshold was 4.0 ......